ArticleCureus2025
John Cunningham (JC) Virus Encephalitis Without Progressive Multifocal Leukoencephalopathy in a Stem Cell Transplant Patient: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
John Cunningham (JC) Virus (JCV) belongs to the Polyomaviridae family and is notorious for remaining latent in the kidneys and lymphoid organs of healthy populations. However, in the setting of profound immunosuppression, the virus can reactivate, leading to various manifestations depending on its location of infection, i.e., progressive multifocal leukoencephalopathy (PML), JC virus encephalopathy, or JC virus granule cell neuronopathy. Here, we present a unique case of a 28-year-old female with a notable medical history of acute myeloid leukemia (AML) status post stem cell transplant who presented to the emergency department (ED) for evaluation of her altered mental status for one week. Laboratory investigations documented the presence of JCV in both the blood and cerebrospinal fluid (CSF). Unlike the typical findings of PML, the brain imaging revealed a 4 mm T2-weighted fluid attenuated inversion recovery (T2/FLAIR) hyperintense enhancing focus in the right supratentorial region and a right anterior temporal subcortical white matter enhancement measuring up to 14 mm in size with no corresponding FLAIR abnormality suggestive of JCV encephalitis. The patient received virus-specific T cells but showed minimal to no improvement. Hence, the patient's family opted for hospice care, but the patient died subsequently. JCV encephalitis is a relatively rare condition; only a few case reports have been reported. The prognosis of JCV encephalitis is not well established and is most often lethal with high viral loads. Virus-specific T-cell therapy has not yet demonstrated the desired clinical benefit; therefore, additional data are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.